The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

SRPT FINANCIAL STATEMENTS

Sarepta Therapeutics Inc — balance sheet, income statement and cash flow trends

SRPTSarepta Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-1 B01 B2 B202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue2 B $Gross Profit1.2 B $ · 59%Operating Income-143.2 M $ · -7%Pre-tax Income-130.9 M $ · -7%Net Income to Owners-136.7 M $ · -7%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue2 B $-20.4%
Gross Profit1.2 B $-41.2%
Operating Income-143.2 M $—
EBITDA-14.6 M $-140.4%
Net Income to Owners-136.7 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
02 B4 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets3.2 B
  • Equity1.5 B $48%
  • Current Liabilities502.9 M $16%
  • Long-term Liabilities1.2 B $36%

Key Figures

YoY change
Total Assets3.2 B $-13.4%
Total Liabilities1.7 B $-28.5%
Total Equity1.5 B $+12.6%
Cash & ST Investments788.5 M $-1.5%
Total Debt1 B $-22.8%
Net Debt474.7 M $-43.7%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-500 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-200 M-100 M0-91.7 M $Operating-33.5 M $Investing-156.5 M $Financing-281.7 M $Net Change

Key Figures

YoY change
Operating Cash Flow-91.7 M $—
Capital Expenditures39.8 M $-74.0%
Free Cash Flow-131.5 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on SRPT

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 11, 26. This content is for informational purposes only and is not investment advice.